Pharmaceuticals News and Research

RSS

Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia

Inspiration Biopharmaceuticals Inc. today announced new license, development and commercialization agreements with its strategic partner, Ipsen.

21 Aug 2012

National approach can help manage drug shortages in Canada

Canada needs a national approach to managing its supply of pharmaceutical drugs, starting with a mandatory reporting system for drug shortages, argues an editorial in CMAJ (Canadian Medical Association Journal) and CPJ (Canadian Pharmacists Journal).

21 Aug 2012

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

ARIAD Pharmaceuticals, Inc. today announced the initiation of a multi-center Phase 1/2 clinical trial in Japan of ponatinib, the Company's investigational BCR-ABL inhibitor.

20 Aug 2012

New evidence reveals possibility of mood-enhancing effects associated with some flavors

New evidence reveals the possibility of mood-enhancing effects associated with some flavors, stemming at least in part from natural ingredients bearing a striking chemical similarity to valproic acid, a widely used prescription mood-stabilizing drug, scientists reported here today. This effect joins those previously reported for chocolate, teas and some other known comfort foods.

20 Aug 2012

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.

18 Aug 2012

Teva launches generic ACTOplus met to improve glucose control in adults with type 2 diabetes

Teva Pharmaceutical Industries Ltd. announced today the launch of an authorized generic of ACTOplus met (pioglitazone/metformin tablets)15 mg/500 mg, 15 mg/850 mg.

18 Aug 2012

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

The U.S. Food and Drug Administration today approved the first generic version of Actos (pioglitazone hydrochloride) tablets. Along with diet and exercise, pioglitazone is used to improve blood glucose control in adults with type 2 diabetes.

18 Aug 2012

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta (linagliptin) tablets for use as add-on therapy to insulin.

18 Aug 2012

Ranbaxy’s generic pioglitazone hydrochloride tablets now available in the U.S.

Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market, under an agreement with Takeda Pharmaceuticals U.S.A., Inc.

17 Aug 2012

Study examines whether eribulin offers added benefit to women with breast cancer

Eribulin was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy.

17 Aug 2012

Roundup: States limit Medicaid mental health prescriptions; Mass. to vote on assisted suicide; Insurer earnings drop in Mass.

Medicaid is the largest funder of mental health services in the United States. In 2008, in all 50 states, Medicaid spent a total of $4.5 billion on behavioral health drugs, about a fifth of the $22.5 billion spent by the program on all pharmaceuticals combined. Roughly a third of the participants in Medicaid and the Children's Health Insurance Program experience a mental health episode annually, according to a 2010 report by the Mental Health Services Administration.

17 Aug 2012

Curcumin shows promise in fighting devastating viruses

The popular spice turmeric packs more than just flavor - it shows promise in fighting devastating viruses, Mason researchers recently discovered.

17 Aug 2012

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Virginia Commonwealth University and Nostrum Pharmaceuticals, LLC, are pleased to announce the signing of a license agreement for the development of inhaled dapsone for the treatment of respiratory diseases.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Seth Lederman, M.D., President and CEO of New York City-based Tonix Pharmaceuticals Holding Corp. (OTCBB:TNXP) says that a good night’s sleep is a potentially powerful, but currently elusive, treatment for the chronic pain and sleep disorders suffered by patients with fibromyalgia (FM), post-traumatic stress disorder (PTSD), traumatic brain injury (TBI) and chronic traumatic encephalopathy (CTE).

16 Aug 2012

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

The head of one of the UK's leading cancer research organisations has hailed a golden age in prostate cancer drug discovery as for the fourth time in two years results are published finding a new drug can significantly extend life.

16 Aug 2012

Scientists researching Ebola virus say vaccine 'unlikely' due to funding restraints

"Scientists researching the lethal Ebola virus have told [BBC News] that a commercial vaccine to prevent the onset of infection may never be developed," the news service reports.

16 Aug 2012

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

The Infectious Disease Research Institute (IDRI), a Seattle-based non-profit research organization that is a leading developer of adjuvants used in vaccines combating infectious disease, and Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles (VLPs), announce that they have been cleared by the U.S. Food and Drug Administration (FDA) to initiate a Phase 1 clinical trial for an H5N1 Avian Influenza VLP vaccine candidate.

16 Aug 2012

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Diffusion Pharmaceuticals LLC, a biotechnology company focused on innovative cancer treatments, today announced that the U.S. Patent and Trademark Office has granted it patent numbers 7919527 and 8030350, entitled "Bipolar Trans Carotenoids Salts and Their Uses" and "Trans Carotenoids, Their Synthesis and Uses," respectively.

16 Aug 2012

Thomson Reuters welcomes GenoSpace to Life Sciences Partner Ecosystem

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced that GenoSpace joined its Life Sciences Partner Ecosystem.

16 Aug 2012

Pharmaceuticals News and Research

Ipsen, Inspiration partner to commercialize IB1001 and OBI-1 for hemophilia

National approach can help manage drug shortages in Canada

ARIAD initiates multi-center ponatinib Phase 1/2 clinical trial for CML in Japan

New evidence reveals possibility of mood-enhancing effects associated with some flavors

Study demonstrates how Elesclomol blocks oxidative phosphorylation in melanoma

Teva launches generic ACTOplus met to improve glucose control in adults with type 2 diabetes

Mylan Pharmaceuticals receives FDA approval for pioglitazone tablets to treat type 2 diabetes

Lilly, Boehringer Ingelheim receive FDA approval for Tradjenta sNDA to treat type 2 diabetes

Ranbaxy’s generic pioglitazone hydrochloride tablets now available in the U.S.

Study examines whether eribulin offers added benefit to women with breast cancer

Roundup: States limit Medicaid mental health prescriptions; Mass. to vote on assisted suicide; Insurer earnings drop in Mass.

Curcumin shows promise in fighting devastating viruses

Nostrum, VCU sign license agreement to develop inhaled dapsone for respiratory diseases

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Potential treatment for sleep disorders suffered by patients with Fibromyalgia, Post-Traumatic Stress Disorder and Traumatic Brain Injury

Enzalutamide drug can extend life and improve QOL in men with advanced prostate cancer

Scientists researching Ebola virus say vaccine 'unlikely' due to funding restraints

Medicago, IDRI receive FDA approval to commence Phase 1 H5N1 vaccine trial

Diffusion Pharmaceuticals receives new U.S. patents for trans sodium crocetinate

Thomson Reuters welcomes GenoSpace to Life Sciences Partner Ecosystem

Event guide: 3rd EHS for Biopharma Summit eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence